These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31336070)

  • 1. Galectin-3 as a Predictor of Long-term Survival After Isolated Coronary Artery Bypass Grafting Surgery.
    Parker DM; Owens SL; Ramkumar N; Likosky D; DiScipio AW; Malenka DJ; MacKenzie TA; Brown JR
    Ann Thorac Surg; 2020 Jan; 109(1):132-138. PubMed ID: 31336070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac Biomarkers Predict Long-term Survival After Cardiac Surgery.
    Ramkumar N; Jacobs JP; Berman RB; Parker DM; MacKenzie TA; Likosky DS; DiScipio A; Malenka DJ; Brown JR
    Ann Thorac Surg; 2019 Dec; 108(6):1776-1782. PubMed ID: 31255614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated preoperative Galectin-3 is associated with acute kidney injury after cardiac surgery.
    Wyler von Ballmoos M; Likosky DS; Rezaee M; Lobdell K; Alam S; Parker D; Owens S; Thiessen-Philbrook H; MacKenzie T; Brown JR
    BMC Nephrol; 2018 Oct; 19(1):280. PubMed ID: 30342486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease.
    Maiolino G; Rossitto G; Pedon L; Cesari M; Frigo AC; Azzolini M; Plebani M; Rossi GP
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):725-32. PubMed ID: 25614283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of Galectin-3 for the occurrence of coronary artery disease and prognosis after myocardial infarction and its association with carotid IMT values in these patients: A mid-term prospective cohort study.
    Lisowska A; Knapp M; Tycińska A; Motybel E; Kamiński K; Święcki P; Musiał WJ; Dymicka-Piekarska V
    Atherosclerosis; 2016 Mar; 246():309-17. PubMed ID: 26828748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Association Between Novel Biomarkers and 1-Year Readmission or Mortality After Cardiac Surgery.
    Jacobs JP; Alam SS; Owens SL; Parker DM; Rezaee M; Likosky DS; Shahian DM; Jacobs ML; Thiessen-Philbrook H; Wyler von Ballmoos M; Lobdell K; MacKenzie T; Everett AD; Parikh CR; Brown JR
    Ann Thorac Surg; 2018 Oct; 106(4):1122-1128. PubMed ID: 29864407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive Ability of Novel Cardiac Biomarkers ST2, Galectin-3, and NT-ProBNP Before Cardiac Surgery.
    Polineni S; Parker DM; Alam SS; Thiessen-Philbrook H; McArthur E; DiScipio AW; Malenka DJ; Parikh CR; Garg AX; Brown JR
    J Am Heart Assoc; 2018 Jul; 7(14):. PubMed ID: 29982227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
    Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
    J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does Preoperative Troponin Level Impact Outcomes After Coronary Artery Bypass Grafting?
    Beller JP; Hawkins RB; Mehaffey JH; LaPar DJ; Kron IL; Yarboro LT; Ailawadi G; Ghanta RK
    Ann Thorac Surg; 2018 Jul; 106(1):46-51. PubMed ID: 29526501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the utility of preoperative versus postoperative B-type natriuretic peptide for predicting hospital length of stay and mortality after primary coronary artery bypass grafting.
    Fox AA; Muehlschlegel JD; Body SC; Shernan SK; Liu KY; Perry TE; Aranki SF; Cook EF; Marcantonio ER; Collard CD
    Anesthesiology; 2010 Apr; 112(4):842-51. PubMed ID: 20216395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Survival Prediction for Coronary Artery Bypass Grafting: Validation of the ASCERT Model Compared With The Society of Thoracic Surgeons Predicted Risk of Mortality.
    Lancaster TS; Schill MR; Greenberg JW; Ruaengsri C; Schuessler RB; Lawton JS; Maniar HS; Pasque MK; Moon MR; Damiano RJ; Melby SJ
    Ann Thorac Surg; 2018 May; 105(5):1336-1343. PubMed ID: 29273200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery.
    Patel DM; Thiessen-Philbrook H; Brown JR; McArthur E; Moledina DG; Mansour SG; Shlipak MG; Koyner JL; Kavsak P; Whitlock RP; Everett AD; Malenka DJ; Garg AX; Coca SG; Parikh CR
    Am Heart J; 2020 Feb; 220():253-263. PubMed ID: 31911262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating systemic fibrosis by combining galectin-3 and ST2 provides powerful risk stratification value for patients after acute decompensated heart failure.
    Wang CH; Yang NI; Liu MH; Hsu KH; Kuo LT
    Cardiol J; 2016; 23(5):563-572. PubMed ID: 27515479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative brain natriuretic peptide predicts late mortality and functional class but not hospital readmission after cardiac surgery.
    Vikholm P; Schiller P; Hellgren L
    J Cardiothorac Vasc Anesth; 2014 Jun; 28(3):520-7. PubMed ID: 24731743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Galectin-3 Following Heart Transplant: Long-term Dynamics and Prognostic Value.
    Suárez-Fuentetaja N; Barge-Caballero E; Bayés-Genís A; Doménech N; Moreda-Santamaría L; Paniagua-Martín MJ; Barge-Caballero G; Couto-Mallón D; Solla-Buceta M; Estévez-Cid F; Cuenca-Castillo JJ; Pombo-Otero J; Grille-Cancela Z; Blanco-Canosa P; Muñiz J; Vázquez-Rodríguez JM; Crespo-Leiro MG
    Rev Esp Cardiol (Engl Ed); 2019 Nov; 72(11):899-906. PubMed ID: 30477951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study.
    Asleh R; Enriquez-Sarano M; Jaffe AS; Manemann SM; Weston SA; Jiang R; Roger VL
    J Am Coll Cardiol; 2019 May; 73(18):2286-2295. PubMed ID: 31072572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists.
    Koukoui F; Desmoulin F; Galinier M; Barutaut M; Caubère C; Evaristi MF; Murat G; De Boer R; Berry M; Smih F; Rouet P
    PLoS One; 2015; 10(3):e0119160. PubMed ID: 25786035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteopontin and galectin-3 predict the risk of ventricular tachycardia and fibrillation in heart failure patients with implantable defibrillators.
    Francia P; Adduci C; Semprini L; Borro M; Ricotta A; Sensini I; Santini D; Caprinozzi M; Balla C; Simmaco M; Volpe M
    J Cardiovasc Electrophysiol; 2014 Jun; 25(6):609-16. PubMed ID: 24400815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.
    Tuegel C; Katz R; Alam M; Bhat Z; Bellovich K; de Boer I; Brosius F; Gadegbeku C; Gipson D; Hawkins J; Himmelfarb J; Ju W; Kestenbaum B; Kretzler M; Robinson-Cohen C; Steigerwalt S; Bansal N
    Am J Kidney Dis; 2018 Oct; 72(4):519-528. PubMed ID: 29866459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma corin decreases after coronary artery bypass graft surgery and is associated with postoperative heart failure: a pilot study.
    Barnet CS; Liu X; Body SC; Collard CD; Shernan SK; Muehlschlegel JD; Jarolim P; Fox AA
    J Cardiothorac Vasc Anesth; 2015 Apr; 29(2):374-81. PubMed ID: 25649697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.